XCel Brands: Q4 Earnings Snapshot
NEW YORK — NEW YORK — XCel Brands Inc. (XELB) on Wednesday reported a loss of $7.1 million in its fourth quarter.
The New York-based company said it had a loss of $3 per share. Losses, adjusted for non-recurring costs and amortization costs, came to 69 cents per share.
The brand management company posted revenue of $1.2 million in the period.
For the year, the company reported a loss of $22.4 million, or $9.84 per share. Revenue was reported as $8.3 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XELB at https://www.zacks.com/ap/XELB
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that during this period, the broader market rose by 1.8%, and has seen a 13% increase over the past year. With market earnings projected to grow 14% annually, the strong performance of CRISPR's stock could be viewed alongside these generally positive trends and any recent but unspecified developments as contributing factors to its upward momentum in the market. Be aware that CRISPR Therapeutics is showing 1 weakness in our investment analysis. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Over the past year, CRISPR Therapeutics' shares experienced a total return of 27.67% decline. This longer-term performance contrasts with the U.S. market's return of 12.6% and the U.S. Biotechs industry return of 9% over the same period. Despite the recent 15.8% increase in CRISPR's stock price over the past month, the longer-term underperformance highlights ongoing challenges. The company's significant net losses and decreasing revenue signal potential hurdles to achieving forecasted revenue growth of 57.32% per year. Earnings forecasts remain bleak, as CRISPR is currently unprofitable and not expected to turn profitable within the next three years. This indicates that while the recent uptick in share price might be aligned with short-term market trends, the company's underlying financial health presents uncertainties. Analyst consensus estimates a fair value price target of US$81.67, which is over twice the current share price. This suggests that the stock is trading at a substantial discount, potentially implying room for future price appreciation if the company can improve its financial metrics. However, it also underscores the risks, given the current unprofitable status and forecasted challenges ahead. Examine CRISPR Therapeutics' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
You can still score the PlayStation DualSense Edge controller at its best-ever price
All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. SAVE $30.99: As of June 6, the PlayStation DualSense Edge Wireless Controller is on sale for $169 at Amazon. That's 15% off its list price of $199.99 and its lowest price yet. Opens in a new window Credit: PlayStation PlayStation DualSense Edge Wireless Controller $169 at Amazon $199.99 Save $30.99 Get Deal PlayStation's Days of Play is still going strong, as are the many great PlayStation deals available right now. If you've been looking to pick up a new controller for your PS5, or an extra for your next co-op session, the PlayStation DualSense Edge Controller is still down to its lowest-ever price at Amazon. The PlayStation DualSense Edge Controller has received a 15% discount at Amazon that has dropped its price from $199.99 to $169. The deal applies to both the midnight black and white versions of the controller as well, so you can scoop up the one that best matches your PS5 setup. SEE ALSO: Get the PlayStation 5 Pro for its lowest-ever price at Target The DualSense Edge has plenty to offer PS5 players, with stick caps you can change out, adjustable triggers, mappable back buttons, and more to help you personalize how you play. The Days of Play sale runs runs through June 11, so act fast to save on the PlayStation DualSense Edge Controller. If you're looking for the standard DualSense controllers instead, those are also on sale right now. Roku Ultra 4K Ultimate Streaming Player (2024 Release) — $79.99 (List Price $99.99) Beats Pill Bluetooth Speaker — $99.95 (List Price $149.95) Roborock Qrevo Master Robot Vacuum and Mop — $899.99 (List Price $1599.99) Apple AirTag (4-Pack) — $74.99 (List Price $99.00) DualSense Edge Wireless Controller — $169.00 (List Price $199.99)
Bloomberg
30 minutes ago
- Bloomberg
Vance Says He Hopes Musk Will 'Come Back Into the Fold'
In a podcast interview with Theo Von "This Past Weekend", Vice President JD Vance share his thoughts Musk's exit from the Trump administration and that he hopes Musk will 'Come Back Into the Fold". (Source: Bloomberg)
